Study: The choice of the right vitamin K2: Menaquinon-4 vs. Menaquinon-7

Veröffentlicht:

Von:

Referenz Abdel-rahman MS, Alkady EA, Ahmed S. Menachinon-7 als neuartige pharmakologische Therapie bei der Behandlung von rheumatoider Arthritis: Eine klinische Studie. Eur J Pharmacol. 15. August 2015;761:273-278. Studienziel Klärung der therapeutischen Rolle der Menachinon-7 (MK-7)-Form von Vitamin K2 zusätzlich zu einem Standardbehandlungsschema für rheumatoide Arthritis (RA) Design Randomisierte klinische Studie Teilnehmer 84 RA-Patienten (24 männlich, 60 weiblich), Durchschnittsalter 47 Jahre, die sich einer Standardbehandlung für RA (Methotrexat-Therapie) unterziehen [MTX]) Intervention Zweiundvierzig Patienten erhielten 100 µg/Tag MK-7, und 42 Patienten dienten als Kontrollen ohne Ergänzung. Studienparameter bewertet Krankheitsaktivitäts-Score zur Bewertung von 28 Gelenken, berechnet mit Erythrozytensedimentationsrate (DAS28-ESR), Matrix-Metalloproteinase (MMP-3), BSG allein, …
Reference Abdel-Rahman MS, Alkady EA, Ahmed S. Menachinon-7 as new pharmacological therapy in the treatment of rheumatoid arthritis: a clinical study. EUR J Pharmacol. August 15, 2015; 761: 273-278. Study goal clarification of the therapeutic role of the Menachinon-7 (MK-7) form of vitamin K2 In addition to a standard treatment scheme for rheumatoid arthritis (RA) design, randomized clinical study participants 84 RA patients (24 male, 60 female), average age 47 years, which are undergoing standard treatment for RA (methotrexate therapy)) Intervention in forty-two patients received 100 µg/day MK-7, and 42 patients served as checks without addition. Study parameters evaluated disease activity score for evaluating 28 joints, calculates with erythrocytensedimentation rate (DAS28-ESR), matrix metaloproteinase (MMP-3), BSG alone, ... (Symbolbild/natur.wiki)

Reference

Abdel-Rahman MS, Alkady EA, Ahmed S. Menachinon-7 as new pharmacological therapy in the treatment of rheumatoid arthritis: a clinical study. EUR J Pharmacol. August 15, 2015; 761: 273-278.

Study goal

Clarification of the therapeutic role of the Menachinon-7 (MK-7) form of vitamin K 2 In addition to a standard treatment scheme for rheumatoid arthritis (ra)

Design

randomized clinical study

participant

84 RA patients (24 male, 60 female), average age 47 years, which undergo standard treatment for RA (methotrexate therapy) [MTX])

Intervention

forty-two patients received 100 µg/day MK-7, and 42 patients served as checks without addition.

study parameters evaluated

Disease activity score for evaluating 28 joints, calculates with erythrocytensedimentation rate (DAS28-ESR), matrix metaloproteinase (MMP-3), BSG alone, C-reactive protein (CRP) and MK-7 serum concentration

important knowledge

The group treated with MK-7 showed a significant decrease in biochemical RA markers compared to controls, including significantly lower CRP, ESR and the28 ESR. This indicates improved disease activity in RA patients and a promising new active ingredient for RA in combination with standard RA treatment.

practice implications

ra is a chronic inflammatory disease that affects several joints. The progressive destruction of the joints mainly depends on the development of hyperplastic synovial tissue, which in turn is a function of dysregulated cell proliferation and apoptosis.
MTX is standard therapy for RA, and it is assumed that its mechanism of action is its inhibiting effect on the hyperplasia of synovial tissue. In theory, other treatments that inhibit synovial hyperplasia have potential for anti-RA therapy.
Menaquinon-7 seems to offer Menaquinon-4 a number of practical advantages in terms of lower dosage and a single daily dosage instead of multiple doses.
vitamin K in the form of Menachinon-4 (MK-4) demonstrably reduces the proliferation of rheumatoid synovial cells in in-vitro and in-vivo models. Reduced. 2.3 For these reasons, MK-4 was recommended as a new means of treating RA either alone or in combination with standard RA therapy.
MK-7 is a form of vitamin k that has greater bioavailability after oral administration, 4 but the therapeutic benefit of MK-7 had not been examined before. The present study showed that the administration of MK-7 (100 µg/day) of RA patients over 3 months reduced the values ​​of CRP, ESR, DES28-ESR and MMP-3, which indicates that this form of vitamin K is also effective when treating RA.
vitamin K 2 occurs in nature in several forms; Each shape is referred to by the length of the side chain (the number of isoprenoid units) of this fat -soluble molecule. Different forms of vitamin K 2 occur in different quantities in foods of different origins. MK-4, a relatively short-chain menachinone, occurs in animal foods such as butter and egg yolk. Long-chain menachinones (MK-5 to MK-10) occur in different quantities in fermented foods such as cheese. 5 MK-7 is the prevailing form of vitamin K 2 NATTO and it is of commercial and clinical interest, as it is slightly available is.
synthetic MK-4 supplements were the first to come on the market and the early research on vitamin k 2 is practically not toxic, so this became a standard dose in research and clinical practice. In a recently carried out study, MK-4 was used in lower doses, e.g. B. 600 µg daily. 6 Further studies are required to confirm whether MK-4 is effective in these lower, dietary doses.
research with the MK-7 form of vitamin K 2 began about a decade ago. Probably due to its longer side chain, which gives greater fat solubility, MK-7 has a much longer half-life than MK-4. This is one main reason that doses of MK-7 can be as low as 45 µg daily and that a single daily dosage is possible. The present study used 100 µg once a day.
Based on this small study, it seems that MK-7 in doses of 100 µg can improve the disease activity value for RA patients for 3 months. This study was limited due to its small size and possible deletion distortation, which was recognized by the authors. However, it confirms the effects previously observed with MK-4 and contributes to knowledge about vitamin K at 2 in both forms available in stores as a potentially helpful means in the treatment of ra.
A worthwhile note for clinicians is that 6 of the 42 patients in the treatment group of this study (approximately 14 % of this small sample) did not improve the activity of the rheumatoid disease and were regarded as non -responder. It was found that MK-7 blood levels were significantly lower in these patients, which indicates differences in absorption and/or in metabolism. No comment was made on how this finding does this compared to the degrees of the non-response for MK-4.
MK-7 seems to offer a number of practical advantages in terms of lower dosage and a single daily dosage instead of multiple cans compared to MK-4. However, in order to fully understand whether 1 type of vitamin k is actually superior to another, more head-to-head studies in which the clinical results of both generally available forms of vitamin K are compared 2

  1. Okamoto H, Shidara K, Hoshi D, Kamatani N. Anti-Arthritis effects of vitamin K (2) (Menachinon-4)-a new potential therapeutic strategy for rheumatoid arthritis. FEBS J. 2007; 274 (17): 4588-4594.
  2. Ebina K., Shi K., Hirao M. et al. The administration of vitamin K2 is associated with reduced disease activity in patients with rheumatoid arthritis. mod rheumatol. 2013; 23 (5): 1001-1007.
  3. Suzuki K., Tsuji S., Fukushima Y., et al. Clinical results of alendronate monotherapy and combination therapy with Menate Strenon (Vitk 2 ) for postmenopausal RA patients. mod rheumatol. 2013; 23 (3): 450-455.
  4. SchURS LJ, Teunissen KJ, Hamulyák K, Knapen MH, VIK H, Vermeer C. Vitamin K-containing dietary supplements: Comparison of synthetic vitamin K1 and NATTO-derived Menachinon-7. blood. 2007; 109 (8): 3279-3283.
  5. rheaume-Bleue K. vitamin K 2 impression. New York: Harper; 2013.
  6. nakamura e, aoki m, watanabe f, kamimura A. low-dosed menachinon-4 improves γ-carboxylation of osteocalcin in young men: an unpladebo-controlled dose effect study. Nutr j. August 27, 2014; 13:85.